Novo Says Cagrisema Was Associated With 25% Mean Weight Loss Among Early Responders In A Post HOC Analysis Of Redefine 1 Presented At Obesityweek® 2026
Nov 15 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO'S CAGRISEMA WAS ASSOCIATED WITH 25% MEAN WEIGHT LOSS AMONG EARLY RESPONDERS IN A POST HOC ANALYSIS OF REDEFINE 1 PRESENTED AT OBESITYWEEK® 2026
NOVO: 67.8% OF ADULTS TREATED WITH INVESTIGATIONAL CAGRISEMA 2.4 MG / 2.4 MG WERE EARLY RESPONDERS, ACHIEVING AT LEAST 5% WEIGHT LOSS BY WEEK 8
NOVO: WOMEN WERE MORE LIKELY TO BE EARLY RESPONDERS THAN DELAYED RESPONDERS
NOVO: MORE ADULTS WITH OVERWEIGHT OR OBESITY TREATED WITH INVESTIGATIONAL CAGRISEMA 2.4 MG REPORTED IMPROVEMENT AT 68 WEEKS
Further company coverage: [NOVOb.CO]